Clinical Trials for COPD
198 copd trials indexed, 87 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding COPD
Chronic Obstructive Pulmonary Disease (COPD) is a group of lung conditions that cause breathing difficulties. The main problem in COPD is damage to the airways and air sacs in the lungs, which makes it hard to move air in and out. This damage is usually permanent and gets worse over time. Doctors diagnose COPD by measuring how much air a person can breathe out in one second using a test called spirometry. This test helps identify airflow obstruction, which is a key sign of COPD.
People with COPD often have symptoms such as chronic cough, shortness of breath, wheezing, and frequent respiratory infections. The condition usually starts to show symptoms in middle-aged or older adults, often after age 40. COPD most commonly affects smokers or former smokers, but exposure to air pollution, dust, and chemicals can also increase risk. Genetic factors may play a role in some cases, especially in people who develop COPD without a history of smoking.
COPD is a serious health issue worldwide. It is the third leading cause of death globally, causing over 3 million deaths annually. In the United States alone, about 16 million people have been diagnosed with COPD, but many more may be undiagnosed. The disease also creates a large economic burden, with billions spent each year on healthcare costs and lost productivity. Because COPD causes long-term disability, it affects not only the health of individuals but also their ability to work and carry out daily activities.
The COPD Treatment Landscape
The first step in treating COPD usually involves lifestyle changes and medications to relieve symptoms and prevent flare-ups. Quitting smoking is the most important action for patients who smoke. Doctors often prescribe inhaled bronchodilators as the first-line treatment. These drugs help open the airways and make breathing easier. Long-acting bronchodilators are commonly used for daily maintenance therapy, while short-acting versions can be used as needed for symptom relief.
If symptoms persist or worsen, additional medications may be added. These include inhaled corticosteroids, which reduce inflammation in the lungs, and combination inhalers that contain both bronchodilators and steroids. Other drug classes used in later stages include phosphodiesterase-4 inhibitors, which help reduce inflammation and relax airways. Oxygen therapy is recommended for patients with low blood oxygen levels, and pulmonary rehabilitation programs can improve exercise capacity and quality of life.
Despite these options, many patients still experience frequent exacerbations or poor symptom control. Some subgroups, such as those with severe COPD or certain genetic profiles, respond less well to existing treatments. Side effects from inhaled steroids, like increased risk of pneumonia, can also limit their use. Research is focusing on new drugs that target different pathways, personalized treatments based on patient characteristics, and better ways to prevent flare-ups. These efforts aim to close gaps in care and improve long-term outcomes.
Why Clinical Trials Matter for COPD
Clinical trials offer patients with COPD the chance to access new treatments that are not yet widely available. Participating in a trial often means closer health monitoring and additional support from the research team. ClinicalTrials.gov currently lists 198 COPD clinical trials, with 87 actively recruiting participants. These studies explore a variety of interventions, from new medications to lifestyle and rehabilitation approaches. By joining a trial, patients contribute to scientific knowledge that can help improve care for others in the future.
It is important to understand that clinical trials also carry risks. Some treatments may not work as hoped, and participants might receive a placebo instead of the active drug. Trials often require extra clinic visits, tests, and procedures that can be time-consuming. Side effects from experimental treatments are possible, and their full safety profiles are not always known. Patients should discuss these factors carefully with their healthcare providers before enrolling.
The sponsors of COPD clinical trials include academic institutions, pharmaceutical companies, and cooperative research groups. Each plays a role in designing and conducting studies to answer specific questions about COPD treatment and management. ClinicalTrials.gov serves as a central registry where patients and caregivers can find detailed information about available studies, eligibility criteria, and contact details. This transparency helps people make informed decisions about participating in research.
What to Look for in a COPD Clinical Trial
Clinical trials are divided into four main phases to test new treatments. Phase 1 trials focus on safety and dosage, usually involving a small group of healthy volunteers or patients. Phase 2 trials look at effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to the current standard, often with hundreds of participants. Phase 4 trials happen after approval to monitor long-term effects. For COPD, many trials do not specify a phase (82), but Phase 3 trials are the most common (20), followed by Phase 2 (19) and Phase 4 (11).
When joining a COPD clinical trial, you will likely need to meet certain inclusion criteria. These often include age limits, typically between 40 and 80 years old, since COPD mainly affects older adults. Prior treatments you have used may be considered, such as inhalers or oxygen therapy. Some trials require specific biomarkers or lung function test results to confirm the stage of COPD. The duration of your disease may also be important, with some studies focusing on recent diagnoses and others on long-term patients.
Exclusion criteria are just as important to protect your safety and the study’s validity. People with serious comorbidities like heart failure or uncontrolled diabetes might be excluded. This is because these conditions can interfere with the treatment or increase risks. Drug interactions are also a concern, so you may be asked to avoid certain medications. Safety thresholds such as kidney or liver function tests help researchers decide if you can safely participate.
Practical factors should also guide your decision to join a trial. Consider the trial length, which can range from a few weeks to several months or years. The number of required visits and their locations matter, especially if travel is difficult. You may want to ask the research team how often you will need to come in, what tests will be done, and if there are costs you should expect. Other useful questions include how your current treatment will be managed, possible side effects, and what happens after the trial ends.
Primary Sources and Further Reading
For more detailed information about COPD and clinical trials, reliable resources are available online. These sources provide trustworthy guidance on COPD management, clinical research, and patient rights. They can help you understand the risks and benefits of participating in a trial. Here are some useful links to explore further.
- National Heart, Lung, and Blood Institute (NHLBI) COPD Information
- MedlinePlus COPD Overview
- ClinicalTrials.gov COPD Studies
- Centers for Disease Control and Prevention COPD Resources
Latest Research and Emerging Treatments for COPD (2026)
Recent COPD research includes several Phase 3 trials testing new drugs that may improve treatment options. One such drug is Tozorakimab, studied in a long-term trial by AstraZeneca (NCT05742802). Tozorakimab targets specific proteins involved in inflammation, which may help reduce flare-ups in people with COPD who have a history of exacerbations. This trial focuses on understanding the safety and effectiveness of Tozorakimab over an extended period, offering hope for better management of symptoms and fewer hospital visits.
Another promising area involves Astegolimab, tested by Hoffmann-La Roche in a long-term safety study (NCT05878769). Astegolimab works by blocking certain immune system signals that can worsen lung inflammation. Early data suggests this drug might help maintain lung function and reduce the risk of COPD flare-ups when used over time. For patients, this could mean a steadier condition with fewer interruptions to daily life.
Sanofi is conducting two trials on Lunsekimig (NCT07190209 and NCT07190222), focusing on adults with COPD that is not well controlled and shows an eosinophilic phenotype. This drug aims to reduce inflammation by targeting cells involved in allergic and inflammatory responses. These studies compare Lunsekimig to placebo to assess its safety and ability to lower exacerbations over about 60 weeks. Additionally, AstraZeneca is testing a combination inhaler containing Budesonide, Glycopyrronium, and Formoterol (NCT06283966) to improve heart and lung health in COPD patients at higher risk of cardiopulmonary problems. This triple therapy is compared to dual therapy to see which better supports overall health. These new drugs for COPD reflect ongoing efforts to provide more personalized and effective copd treatment options in 2026.
Frequently asked questions about COPD trials
How do I find COPD clinical trials?
The authoritative source for COPD clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 198 copd studies are currently indexed. You can search by entering "copd" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new copd trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most COPD trials in?
Across the 198 copd trials TrialsAlert indexes, the most common phase is Phase 3. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many COPD clinical trials are currently recruiting?
As of the latest scan, 87 copd trials have a "Recruiting" status on ClinicalTrials.gov, out of 198 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting copd trial matches their tracked condition.
Stay informed about copd research
Get a weekly briefing with the trials that matter most.